Jackie Shang
Johnson & Johnson (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Diabetes Treatment and Management, Pancreatic function and diabetes, Receptor Mechanisms and Signaling, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2006)121 cited
- → Fluoroolefins as amide bond mimics in dipeptidyl peptidase IV inhibitors(2008)106 cited
- → Discovery of a Novel Glucagon Receptor AntagonistN-[(4-{(1S)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes(2012)86 cited
- → Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure–Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program(2016)20 cited
- → Bioactivation of GPR40 Agonist MK-8666: Formation of Protein Adducts in Vitro from Reactive Acyl Glucuronide and Acyl CoA Thioester(2019)19 cited
- → A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery(2020)18 cited
- → Metabolic Activation and Major Protein Target of a 1-Benzyl-3-carboxyazetidine Sphingosine-1-phosphate-1 Receptor Agonist(2012)16 cited
- → Rat liver microsomal enzyme catalyzed oxidation of 4-phenyl-trans-1-(2-phenylcyclopropyl)-1,2,3,6-tetrahydropyridine(2001)10 cited
- → Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947(2020)9 cited
- → Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists(2011)9 cited